Ligand Pharmaceuticals (LGND) Declines More Than Market: Some Information for Investors
https://www.zacks.com/stock/news/2241058/ligand-pharmaceuticals-lgnd-declines-more-than-market-some-information-for-investors?cid=CS-ZC-FT-tale_of_the_tape|yseop_template_6v2-2241058
Mar 14, 2024 - Ligand Pharmaceuticals (LGND) reachead $71.93 at the closing of the latest trading day, reflecting a -1.14% change compared to its last close.
0
Ligand Pharmaceuticals (LGND) Stock Dips While Market Gains: Key Facts
https://www.zacks.com/stock/news/2251479/ligand-pharmaceuticals-lgnd-stock-dips-while-market-gains-key-facts?cid=CS-ZC-FT-tale_of_the_tape|yseop_template_6v2-2251479
Apr 05, 2024 - Ligand Pharmaceuticals (LGND) closed at $77.96 in the latest trading session, marking a -0.03% move from the prior day.
0
Will Alkermes' (ALKS) Proprietary Drugs Aid Amid Competition?
https://www.zacks.com/stock/news/2259547/will-alkermes-alks-proprietary-drugs-aid-amid-competition?cid=CS-ZC-FT-analyst_blog|zer_report_update-2259547
Apr 22, 2024 - Alkermes (ALKS) expects its set of proprietary products, Vivitrol, Aristada and Lybalvi, to generate incremental sales and combat stiff competition in 2024.
0
Sanofi (SNY) Rilzabrutinib Shows Benefit in Blood Disorder Study
https://www.zacks.com/stock/news/2260438/sanofi-sny-rilzabrutinib-shows-benefit-in-blood-disorder-study?cid=CS-ZC-FT-analyst_blog|company_news_-_medical_sector-2260438
Apr 23, 2024 - Sanofi's (SNY) BTK inhibitor, rilzabrutinib, demonstrates durable platelet response in the phase III LUNA 3 study in adult patients with immune thrombocytopenia.
0
Corcept (CORT) Posts Positive Data From Cushing's Syndrome Study
https://www.zacks.com/stock/news/2260461/corcept-cort-posts-positive-data-from-cushing-s-syndrome-study?cid=CS-ZC-FT-analyst_blog|company_news_-_medical_sector-2260461
Apr 23, 2024 - Corcept (CORT) reports positive data from the open-label portion of the phase III GRACE study evaluating relacorilant for treating patients with Cushing's syndrome.
0
Alkermes' (ALKS) Q1 Earnings & Revenues Fall Shy of Estimates
https://www.zacks.com/stock/news/2267253/alkermes-alks-q1-earnings-revenues-fall-shy-of-estimates?cid=CS-ZC-FT-analyst_blog|earnings_article-2267253
May 02, 2024 - Alkermes' (ALKS) earnings and revenues miss first-quarter 2024 estimates. However, revenues rise year over year on strong proprietary product sales.
0
Repligen (RGEN) Q1 Earnings Miss, Revenues Beat Estimates
https://www.zacks.com/stock/news/2267231/repligen-rgen-q1-earnings-miss-revenues-beat-estimates?cid=CS-ZC-FT-analyst_blog|earnings_article-2267231
May 02, 2024 - Repligen's (RGEN) first-quarter 2024 earnings miss estimates while revenues beat the same.
0
Puma Biotechnology's (PBYI) Q1 Earnings and Revenues Beat
https://www.zacks.com/stock/news/2268089/puma-biotechnology-s-pbyi-q1-earnings-and-revenues-beat?cid=CS-ZC-FT-analyst_blog|earnings_article-2268089
May 03, 2024 - Puma Biotechnology (PBYI) reports narrower-than-expected first-quarter 2024 loss. The company maintains its revenue guidance for 2024.
0
Ligand Pharmaceuticals Incorporated (LGND) Q1 2024 Earnings Call Transcript
https://seekingalpha.com/article/4690546-ligand-pharmaceuticals-incorporated-lgnd-q1-2024-earnings-call-transcript?source=feed_sector_transcripts
May 07, 2024 - Ligand Pharmaceuticals Incorporated (NASDAQ:NASDAQ:LGND) Q1 2024 Earnings Conference Call May 7, 2024 4:30 PM ETCompany ParticipantsMichael Jeong - Investor...
0
Intra-Cellular (ITCI) Q1 Earnings and Sales Beat Estimates
https://www.zacks.com/stock/news/2270731/intra-cellular-itci-q1-earnings-and-sales-beat-estimates?cid=CS-ZC-FT-analyst_blog|earnings_article-2270731
May 08, 2024 - Intra-Cellular (ITCI) reports first-quarter 2024 results, wherein both earnings and revenues beat estimates, driven by strong Caplyta sales.
0
Page 1>